Societal preference values for advanced melanoma health states in the United Kingdom and Australia. - Wikidata - awgldk - TriplyDB

Societal preference values for advanced melanoma health states in the United Kingdom and Australia.

Societal preference values for advanced melanoma health states in the United Kingdom and Australia.

http://www.wikidata.org/entity/Q37287470

about

Cost-effectiveness of treatment strategies for BRAF-mutated metastatic melanoma Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study.Patient-reported utilities in advanced or metastatic melanoma, including analysis of utilities by time to death.Assessment of patient-reported outcomes in patients with melanoma.Cost Effectiveness of Sequencing 34 Cancer-Associated Genes as an Aid for Treatment Selection in Patients with Metastatic Melanoma.Targeted Therapies Compared to Dacarbazine for Treatment of BRAF(V600E) Metastatic Melanoma: A Cost-Effectiveness Analysis Development of the multi-attribute Adolescent Health Utility Measure (AHUM).Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma.Population preference values for health states in relapsed or refractory B-precursor acute lymphoblastic leukemia in the United Kingdom Quality of life valuations of HPV-associated cancer health states by the general population.Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma.Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada A systematic review of utility values for chemotherapy-related adverse events.Vemurafenib for the treatment of locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma: a NICE single technology appraisal.Are the true impacts of adverse events considered in economic models of antineoplastic drugs? A systematic review.Cost-effectiveness of therapies for melanoma.Multiple treatment comparison of seven new drugs for patients with advanced malignant melanoma: a systematic review and health economic decision model in a Norwegian setting.Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States.Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom.Development of a transformation model to derive general population-based utility: Mapping the pruritus-visual analog scale (VAS) to the EQ-5D utility.A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-mutated melanoma in the Swiss setting.Patient preferences for treating refractory overactive bladder in the UK.Cost-effectiveness of vedolizumab compared with conventional therapy for ulcerative colitis patients in the UK.Societal preferences for adjuvant melanoma health states: UK and Australia.Cost-effectiveness of a FISH assay for the diagnosis of melanoma in the USA.Modeling the economic outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomes.Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation Cost-effectiveness of ustekinumab in moderate to severe Crohn's disease in Sweden

P2860

Q28542877-2CC5C57E-4402-4419-98D4-C3A65380FE7B Q33934317-067EF2FF-5C2A-40D5-A31B-240F28509172 Q34235050-8068DC55-31A9-4E59-B25D-40A11AC4CE0F Q34371938-891912C5-562D-4BA5-8021-87B44CFDF154 Q35749307-C21DE506-C993-4948-9F41-C47F03592435 Q35773340-3A826071-9B86-4FD9-B5DD-4804FC947C91 Q36281525-628C7858-E959-4065-A42D-CC127D4F0C16 Q36286084-199DC657-C6BB-426D-8CC2-5B1EB326AFCD Q36287149-6CBB181C-4C89-43A5-B01D-FC1E45DCBC98 Q36678377-2793EEDB-05D1-4C71-87EE-086F9B674B3B Q37003295-3656C62C-A837-4FC4-BFA3-3C16FF9615B5 Q37152908-3CF33CFD-E8BD-4ABF-9573-27E1187E08D0 Q38093053-5F9E93FD-EA0E-456F-8D08-BB647FDA7D89 Q38151578-7EB90786-0B23-47A5-8190-7549755433B3 Q38152967-AA4F28EE-D12E-407E-8349-C29BE3D363DC Q38363756-832EA232-FF75-4FA6-8451-DC3E1D57660E Q38615575-DC55E5B1-0C80-40F6-A656-97633083F05C Q38680945-D40C9610-CE51-4F42-B220-F935F925AF6E Q38921971-86BD9A26-F1DC-4F7F-B96F-A7D7B8CDE605 Q38962798-5E97B1A2-48DB-43DE-8E24-7DF9D383D896 Q38968155-68C30979-78F0-49C8-8895-1FF448FF07F2 Q40565062-7F92A9E0-D828-4D63-813F-68BA0950BC07 Q42649795-D5D60D04-C39F-47B1-9005-5686A28C091C Q42682350-0C3F4137-C8D6-477D-9E54-894693D1AFE8 Q45661783-AC1BA582-B826-4991-A5F2-512807A5DE39 Q55252091-CDBB7995-D38D-4ACF-8782-F60884CF1D2E Q58737536-68B1D998-94B8-42DD-8F2E-FACFEDAD5E3E Q58803120-E551266B-6136-4F7C-A6D3-80DA7FA3AB0D

P2860

Societal preference values for advanced melanoma health states in the United Kingdom and Australia.

http://www.wikidata.org/entity/Q37287470

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 14 July 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Societal preference values for ...... United Kingdom and Australia.

@en

Societal preference values for ...... United Kingdom and Australia.

@nl

type

label

Societal preference values for ...... United Kingdom and Australia.

@en

Societal preference values for ...... United Kingdom and Australia.

@nl

prefLabel

Societal preference values for ...... United Kingdom and Australia.

@en

Societal preference values for ...... United Kingdom and Australia.

@nl

P1433

Q37287470-7311329C-F1E6-469A-944F-826A03E1CD0E

P1476

Q37287470-6EAE5688-1CC2-4F07-91F7-79781503F6A9

P2093

Q37287470-088EAFA7-3EDC-4395-8CBA-B12E312FB3EF

Q37287470-27C76DD4-A011-45B5-A2DA-677FCFBA0FD6

Q37287470-350B4F04-6F2E-4C8B-B2E0-A65771B12C4A

Q37287470-61B3AD94-24F2-4A8A-A9D7-7AF7BC02D384

Q37287470-BD703E0E-9C95-490A-8AA8-6959915D1A24

Q37287470-BF10986E-C0BA-4803-BD10-9BE035C41FF3

Q37287470-D45EAB5C-E953-4483-960C-6634E983E914

Q37287470-DB357310-8ECD-4162-BA3C-6DD399844113

P2860

Q37287470-0D5A7A45-11E2-4BAE-9148-750378763F01

Q37287470-162B6646-4FDB-4D67-A328-21E09B62997C

Q37287470-1A6A3D24-0356-48B3-9192-0C66AC1DBC08

Q37287470-34032E00-7C65-4C55-B097-3C0F84E01FEA

Q37287470-39E6164F-720E-4691-BACC-1654BD6AC456

Q37287470-3E76C12C-153A-4201-A14B-2BAD8E3A01D4

Q37287470-40EE62F8-1621-4457-998F-58C744ECD976

Q37287470-53E6C0C9-D173-44E9-850E-DC7445691721

Q37287470-67C454AF-2DC9-4621-9326-9788E3D28D07

Q37287470-762597C9-89AE-49DC-8ED1-DAC44D5DF50B

P2888

Q37287470-47827FE7-1F52-4F1E-BD84-23DF77950EE6

P304

Q37287470-9350170C-6BAB-49EC-97E7-2EDA33AF6B89

P31

Q37287470-93763556-464E-471A-91AE-2BF63C22F093

P356

Q37287470-5FCEBDA2-4076-4C3E-8737-A91B4CC22A65

P407

Q37287470-8836CE63-467B-43A8-BCE7-49EF8D4261C0

P433

Q37287470-218FFA42-1F1D-45E3-B3E8-B66FF4299010

P478

Q37287470-60DEF117-4B86-4EAB-A875-D3C3F2DAF723

P577

Q37287470-67E0CFD9-7D4A-40F2-8EA3-A7A1C0485432

P5875

Q37287470-E385F014-9B4A-4F41-AC3F-FB0CE257DA79

P698

Q37287470-9DC0A254-E2FD-4EED-808C-B216136E7CFB

P921

Q37287470-5D74BEA4-FDEE-44EF-B633-15EF39EA6696

P932

Q37287470-7FEC06BC-7920-43CC-AD68-5912C8CD2B87

P356

P1433

British Journal of Cancer

P1476

Societal preference values for ...... United Kingdom and Australia.

@en

P2093

A Hoos

http://www.w3.org/2001/XMLSchema#string

A R Levy

http://www.w3.org/2001/XMLSchema#string

J Mukherjee

http://www.w3.org/2001/XMLSchema#string

K M Beusterien

http://www.w3.org/2001/XMLSchema#string

M R Middleton

http://www.w3.org/2001/XMLSchema#string

P Hersey

http://www.w3.org/2001/XMLSchema#string

S Kotapati

http://www.w3.org/2001/XMLSchema#string

S M Szabo

http://www.w3.org/2001/XMLSchema#string

P2860

Patient preferences for adjuvant interferon alfa-2b treatment.

Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data.

Measurement of health state utilities for economic appraisal.

Cost effectiveness and cost utility of adjuvant interferon alpha in cutaneous melanoma: a review.

Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade.

Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: results from randomised trial.

Health utilities using the EQ-5D in studies of cancer.

Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies.

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials.

Deriving utility scores for co-morbid conditions: a test of the multiplicative model for combining individual condition scores.

P2888

P304

387-389

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6605187

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

101

http://www.w3.org/2001/XMLSchema#string

P577

2009-07-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26671611

http://www.w3.org/2001/XMLSchema#string

P698

19603025

http://www.w3.org/2001/XMLSchema#string

P921

P932

2720221

http://www.w3.org/2001/XMLSchema#string